Biohackers seeking to free science and scientific achievement from the ivory tower have come to realize that they may have to borrow from its conventions.
Automated benchtop systems are beginning to integrate oligonucleotide synthesis and protein production. Given economic pressures to innovate in drug manufacture and the potential of platform production technologies to enable decentralization, a future in which the brand manufacturers’ monopoly on biologics could be broken is feasible.
DIY CRISPR kits are under the US Food and Drug Administration's (FDA) jurisdiction, but the FDA has not yet enforced any standards for biohackers.
The growing popularity of genome editing means that these technologies are no longer restricted to laboratories where there is some degree of oversight and regulatory processes; they now extend to the everyman’s garage.
The participants had all flocked to MIT for a three-day summit of biohackers from around the world, an event with the aim of democratizing science, taking technology that’s often hidden in keycard-access labs and bringing it to the people.
The experiments and business activities of the biohacker community have aroused increasing attention from the US Food and Drug Administration (FDA).
The stakes in biohacking seem to be getting higher and higher.
With do-it-yourself Crispr kits now available online, Hannah Devlin asks if it’s really possible to edit your own DNA.
The American Society of Gene and Cell Therapy (ASGCT), the largest organization of scientists who work in gene and cell therapy, has come out against DIY gene therapies.
The US Food and Drug Administration (FDA) statement cautioned that it is illegal to sell gene therapy products and kits intended for self-administration.